Oral controlled release dosage forms. II. Glassy polymers in hydrophilic matrices

被引：16

作者：

Veiga, F ^{[1
]}

Salsa, T ^{[1
]}

Pina, ME ^{[1
]}

机构：

[1] Univ Coimbra, Fac Pharm, Lab Galen & Pharmaceut Technol, P-3049 Coimbra, Portugal

来源：

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY | 1998年 / 24卷 / 01期

关键词：

D O I：

10.3109/03639049809082346

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Part I of this article reported general considerations of oral controlled release dosage forms and the applications of cellulose ether polymers in hydrophilic matrices. Part II of this study describes the advantages and disadvantages of limited swelling hydrophilic matrices, their preparation, mechanism, and parameters affecting drug release from these systems.

引用

页码：1 / 9

页数：9

共 50 条

[41] Low temperature vacuum drying: Evaluation of excipients for injectable dosage forms. II [J].

Flora, KP ;

Blumberg, J ;

LoBianco, I ;

Flora, KP ;

Flora, KA .

ANNALS OF ONCOLOGY, 1998, 9 :47-47

[42] KINETICS IN SOLUTE RELEASE FROM HYDROPHILIC MATRIX EXTENDED-RELEASE DOSAGE FORMS [J].

SKOUG, JW ;

GAO, P ;

NIXON, PR ;

JU, R .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 :101-ANYL

[43] Preformulation considerations for controlled release dosage forms: Part II - Selected candidate support [J].

Chrzanowski, Frank .

AAPS PHARMSCITECH, 2008, 9 (02) :639-645

[44] THE INVITRO DEVELOPMENT OR ORAL EXTENDED RELEASE DOSAGE FORMS [J].

LEESON, LJ .

PHARMAZEUTISCHE INDUSTRIE, 1986, 48 (05) :519-521

[45] SCALEUP OF ORAL EXTENDED-RELEASE DOSAGE FORMS [J].

SKELLY, JP ;

VANBUSKIRK, GA ;

ARBIT, HM ;

AMIDON, GL ;

AUGSBURGER, L ;

BARR, WH ;

BERGE, S ;

CLEVENGER, J ;

DIGHE, S ;

FAWZI, M ;

FOX, D ;

GONZALEZ, MA ;

GRAY, VA ;

HOIBERG, C ;

LEESON, LJ ;

LESKO, L ;

MALINOWSKI, H ;

NIXON, PR ;

PEARCE, DM ;

PECK, G ;

PORTER, S ;

ROBINSON, J ;

SAVELLO, DR ;

SCHWARTZ, P ;

SCHWARTZ, JB ;

SHAH, VP ;

SHANGRAW, R ;

THEEUWES, F ;

WHEATLEY, T .

PHARMACEUTICAL RESEARCH, 1993, 10 (12) :1800-1807

[46] ORAL MODIFIED RELEASE DOSAGE FORMS - QUO VADIS [J].

Baumgartner, S. .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 :26-27

[47] Preformulation Considerations for Controlled Release Dosage Forms: Part II—Selected Candidate Support [J].

Frank Chrzanowski .

AAPS PharmSciTech, 2008, 9 :639-645

[48] IMMEDIATE RELEASE ORAL SOLID DOSAGE FORMS: A REVIEW [J].

Pawar, Dinesh Chhotu ;

Kale, Vrushali Rajkumar ;

Ige, Pradyumna P. .

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (05) :10595-10610

[49] BIOPHARMACEUTICAL ASSESSMENT OF MODIFIED RELEASE ORAL DOSAGE FORMS [J].

MOLLER, H .

PHARMAZEUTISCHE INDUSTRIE, 1986, 48 (05) :514-519

[50] BIOPHARMACEUTICAL ASPECTS OF ORAL MODIFIED RELEASE DOSAGE FORMS [J].

Bogataj, M. .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 :30-31

← 1 2 3 4 5 →